See every side of every news story
Published loading...Updated

Targeted in Vivo Gene Integration of a Secretion-Enabled GLP-1 Receptor Agonist Reverses Diet-Induced Non-Genetic Obesity and Pre-Diabetes

JAPAN, JUL 9 – Researchers created a one-time genome editing treatment enabling mice to produce weight-loss drugs internally, potentially improving adherence and reducing treatment duration, study shows.

Summary by Nature
In vivo genome editing offers a long-term therapeutic approach for monogenic diseases by directly modifying genetic sequences. However, its application to non-monogenic, noncommunicable diseases, which are the leading causes of global mortality, remains limited due to the lack of well-defined genetic targets. We developed an in vivo genome-editing approach to introduce a gene encoding the glucagon-like peptide-1 (GLP-1) receptor agonist Exendin-…

7 Articles

All
Left
Center
2
Right
sport.essport.es
Reposted by
elcorreoweb.eselcorreoweb.es

In recent years, drugs such as Ozempic have led to a genuine medical revolution in the treatment of obesity and type 2 diabetes. These drugs act by imitating the function of LPG-1; a hormone that regulates appetite and glucose levels, to reduce hunger, improve blood sugar control and promote weight loss. Its creators claim that these tools can achieve "spectacular" results but that, in order to achieve all its benefits and maintain its effects, …

Read Full Article

That's an excellent alternative to Ozempic.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medical Xpress broke the news in on Wednesday, July 9, 2025.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.